Compare HCAC & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCAC | AVTX |
|---|---|---|
| Founded | 2025 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.0M | 328.4M |
| IPO Year | N/A | 2015 |
| Metric | HCAC | AVTX |
|---|---|---|
| Price | $10.01 | $16.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $40.57 |
| AVG Volume (30 Days) | 41.3K | ★ 2.2M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $9.92 | $3.43 |
| 52 Week High | $10.06 | $24.27 |
| Indicator | HCAC | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.72 | 47.87 |
| Support Level | N/A | $13.70 |
| Resistance Level | N/A | $19.39 |
| Average True Range (ATR) | 0.01 | 1.98 |
| MACD | 0.01 | -0.36 |
| Stochastic Oscillator | 87.50 | 23.65 |
Hall Chadwick Acquisition Corp is a blank check company.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.